These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 18668570)

  • 1. Is imatinib mesylate a promising drug in systemic sclerosis?
    van Daele PL; Dik WA; Thio HB; van Hal PT; van Laar JA; Hooijkaas H; van Hagen PM
    Arthritis Rheum; 2008 Aug; 58(8):2549-52. PubMed ID: 18668570
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Imatinib mesylate reduces production of extracellular matrix and prevents development of experimental dermal fibrosis.
    Distler JH; Jüngel A; Huber LC; Schulze-Horsel U; Zwerina J; Gay RE; Michel BA; Hauser T; Schett G; Gay S; Distler O
    Arthritis Rheum; 2007 Jan; 56(1):311-22. PubMed ID: 17195235
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Imatinib mesylate treatment of nephrogenic systemic fibrosis.
    Kay J; High WA
    Arthritis Rheum; 2008 Aug; 58(8):2543-8. PubMed ID: 18668587
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The effect of imatinib (Glivec) on scleroderma and normal dermal fibroblasts: a preclinical study.
    Soria A; Cario-André M; Lepreux S; Rezvani HR; Pasquet JM; Pain C; Schaeverbeke T; Mahon FX; Taïeb A
    Dermatology; 2008; 216(2):109-17. PubMed ID: 18216472
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Smad1 pathway is activated in systemic sclerosis fibroblasts and is targeted by imatinib mesylate.
    Pannu J; Asano Y; Nakerakanti S; Smith E; Jablonska S; Blaszczyk M; ten Dijke P; Trojanowska M
    Arthritis Rheum; 2008 Aug; 58(8):2528-37. PubMed ID: 18668566
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Imatinib mesylate in scleroderma-associated diffuse skin fibrosis: a phase II multicentre randomized double-blinded controlled trial.
    Prey S; Ezzedine K; Doussau A; Grandoulier AS; Barcat D; Chatelus E; Diot E; Durant C; Hachulla E; de Korwin-Krokowski JD; Kostrzewa E; Quemeneur T; Paul C; Schaeverbeke T; Seneschal J; Solanilla A; Sparsa A; Bouchet S; Lepreux S; Mahon FX; Chene G; Taïeb A
    Br J Dermatol; 2012 Nov; 167(5):1138-44. PubMed ID: 23039171
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment of pulmonary fibrosis for twenty weeks with imatinib mesylate in a patient with mixed connective tissue disease.
    Distler JH; Manger B; Spriewald BM; Schett G; Distler O
    Arthritis Rheum; 2008 Aug; 58(8):2538-42. PubMed ID: 18668536
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A potential role for imatinib and other small molecule tyrosine kinase inhibitors in the treatment of systemic and localized sclerosis.
    Bibi Y; Gottlieb AB
    J Am Acad Dermatol; 2008 Oct; 59(4):654-8. PubMed ID: 18571768
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy of imatinib mesylate in the treatment of refractory sclerodermatous chronic GVHD.
    Magro L; Catteau B; Coiteux V; Bruno B; Jouet JP; Yakoub-Agha I
    Bone Marrow Transplant; 2008 Dec; 42(11):757-60. PubMed ID: 18762765
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tyrosine kinase inhibitors for the treatment of fibrotic diseases such as systemic sclerosis: towards molecular targeted therapies.
    Distler JH; Distler O
    Ann Rheum Dis; 2010 Jan; 69 Suppl 1():i48-51. PubMed ID: 19995744
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [A new therapeutic avenue for severe systemic sclerosis: imatinib mesylate].
    Taïeb A; Constans J; Mahon FX
    Rev Med Interne; 2008 Mar; 29(3):173-5. PubMed ID: 17597261
    [No Abstract]   [Full Text] [Related]  

  • 12. Efficacy of low-dose imatinib mesylate for cutaneous involvement in systemic sclerosis: a preliminary report of three cases.
    Tamaki Z; Asano Y; Hatano M; Yao A; Kawashima T; Tomita M; Kinugawa K; Nagai R; Sato S
    Mod Rheumatol; 2012 Feb; 22(1):94-9. PubMed ID: 21633912
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Imatinib mesylate inhibits proliferation and exerts an antifibrotic effect in human breast stroma fibroblasts.
    Gioni V; Karampinas T; Voutsinas G; Roussidis AE; Papadopoulos S; Karamanos NK; Kletsas D
    Mol Cancer Res; 2008 May; 6(5):706-14. PubMed ID: 18505916
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Imatinib mesylate for children with dermatofibrosarcoma protuberans (DFSP).
    Gooskens SL; Oranje AP; van Adrichem LN; de Waard-van der Spek FB; den Hollander JC; van de Ven CP; van den Heuvel-Eibrink MM
    Pediatr Blood Cancer; 2010 Aug; 55(2):369-73. PubMed ID: 20582941
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rhabdomyosarcomatous differentiation in gastrointestinal stromal tumors after tyrosine kinase inhibitor therapy: a novel form of tumor progression.
    Liegl B; Hornick JL; Antonescu CR; Corless CL; Fletcher CD
    Am J Surg Pathol; 2009 Feb; 33(2):218-26. PubMed ID: 18830121
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Therapeutic inhibition of tyrosine kinases in systemic sclerosis: a review of published experience on the first 108 patients treated with imatinib.
    Bournia VK; Evangelou K; Sfikakis PP
    Semin Arthritis Rheum; 2013 Feb; 42(4):377-90. PubMed ID: 22789835
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bullous pemphigoid associated with hypereosinophilic syndrome: simultaneous response to imatinib.
    Hofmann SC; Technau K; Müller AM; Lübbert M; Bruckner-Tuderman L
    J Am Acad Dermatol; 2007 May; 56(5 Suppl):S68-72. PubMed ID: 17097375
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Imatinib mesylate inhibits platelet derived growth factor stimulated proliferation of rheumatoid synovial fibroblasts.
    Sandler C; Joutsiniemi S; Lindstedt KA; Juutilainen T; Kovanen PT; Eklund KK
    Biochem Biophys Res Commun; 2006 Aug; 347(1):31-5. PubMed ID: 16806061
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Imatinib for the treatment of refractory, diffuse systemic sclerosis.
    Sfikakis PP; Gorgoulis VG; Katsiari CG; Evangelou K; Kostopoulos C; Black CM
    Rheumatology (Oxford); 2008 May; 47(5):735-7. PubMed ID: 18326532
    [No Abstract]   [Full Text] [Related]  

  • 20. Negative results of an Italian Group for Mesothelioma (G.I.Me.) pilot study of single-agent imatinib mesylate in malignant pleural mesothelioma.
    Porta C; Mutti L; Tassi G
    Cancer Chemother Pharmacol; 2007 Jan; 59(1):149-50. PubMed ID: 16636799
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.